Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EBIT (2016 - 2025)

Marimed (MRMD) has disclosed EBIT for 15 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 18.88% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $479000.0, a 92.89% decrease, with the full-year FY2024 number at $2.9 million, down 79.76% from a year prior.
  • EBIT was $1.6 million for Q3 2025 at Marimed, up from $1.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $12.0 million in Q2 2021 to a low of -$1.4 million in Q4 2024.
  • A 5-year average of $3.5 million and a median of $3.1 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: skyrocketed 598.68% in 2021, then crashed 158.48% in 2024.
  • Marimed's EBIT stood at $1.2 million in 2021, then skyrocketed by 156.68% to $3.1 million in 2022, then fell by 21.95% to $2.4 million in 2023, then plummeted by 158.48% to -$1.4 million in 2024, then soared by 213.4% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EBIT are $1.6 million (Q3 2025), $1.1 million (Q2 2025), and -$851000.0 (Q1 2025).